KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Operations (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Cash from Operations for 13 consecutive years, with 4680000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 54.63% to 4680000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 39637000.0 through Dec 2025, up 38.88% year-over-year, with the annual reading at 39637000.0 for FY2025, 38.88% up from the prior year.
  • Cash from Operations hit 4680000.0 in Q4 2025 for Arbutus Biopharma, up from 5817000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 20619000.0 in Q1 2022 to a low of 27301000.0 in Q1 2023.
  • Historically, Cash from Operations has averaged 14665550.0 across 5 years, with a median of 17141000.0 in 2022.
  • Biggest five-year swings in Cash from Operations: skyrocketed 215.31% in 2022 and later plummeted 232.41% in 2023.
  • Year by year, Cash from Operations stood at 19606000.0 in 2021, then grew by 13.34% to 16990000.0 in 2022, then dropped by 1.78% to 17292000.0 in 2023, then surged by 40.35% to 10315000.0 in 2024, then skyrocketed by 54.63% to 4680000.0 in 2025.
  • Business Quant data shows Cash from Operations for ABUS at 4680000.0 in Q4 2025, 5817000.0 in Q3 2025, and 15749000.0 in Q2 2025.